Seattle Genetics said Tuesday it has initiated a 60-patient clinical trial of an experimental cancer therapy for chronic lymphocytic leukemia...
Seattle Genetics said Tuesday it has initiated a 60-patient clinical trial of an experimental cancer therapy for chronic lymphocytic leukemia (CLL).
SGN-40, a genetically engineered monoclonal antibody, is already being studied for multiple myeloma and non-Hodgkin’s lymphoma in other early trials.
The Bothell company also said SGN-40 received “orphan drug” designation for CLL from the Food and Drug Administration. The designation, for treatment of relatively rare diseases, means Seattle Genetics will have seven years of market exclusivity if the drug is approved.
The company’s stock lost 8 cents, or 1.6 percent, to close at $4.93 Tuesday. It fell 3 more cents in after-hours trading.
Most Read Stories
- Marshawn Lynch takes out a full-page ad in the Seattle Times to thank fans
- Starbucks' Dragon Frappuccino is new 'secret' drink craze
- First reaction: Seahawks select 6 players in second and third rounds of NFL Draft
- For Seahawks, life after Legion of Boom coming faster than we thought based on this NFL draft | Larry Stone
- 2017 NFL draft: Live Seahawks updates from the final day, rounds 4-7